Eli Lilly to buy Versanis for up to $1.93 billion in obesity drug push
Eli Lilly and Co said on Friday it will acquire Versanis, a privately held biotech company developing a novel obesity drug, for potentially up to $1.93 billion, as it seeks to expand its presence in the lucrative weight-loss market. The…